The State of Diabetes Research in the U.S.
Diabetes affects tens of millions of Americans, and the search for better management tools has never been busier. At the American Diabetes Association's Scientific Sessions in New Orleans this year, researchers presented head-to-head data showing that newer oral GLP-1 medications can improve glucose control and support weight loss in people with type 2 diabetes. The ACHIEVE trials compared two oral GLP-1 receptor agonists directly, marking the first time such a comparison has been published. For people who cannot tolerate injections or prefer pills, this is meaningful progress.
Beyond medications, continuous glucose monitoring (CGM) continues to gain ground. A systematic review of thirteen randomized controlled trials found that people with insulin-treated type 2 diabetes who used CGM saw better long-term glucose control and fewer low blood sugar events compared to traditional fingerstick testing. The difference is not always dramatic, but for anyone dealing with overnight lows or unpredictable swings, real-time data changes daily life.
Trials are also branching into surprising areas. At UNC Health in Chapel Hill, researchers treated the first U.S. patient using an investigational endoscopic procedure that gently resurfaces part of the small intestine to address abnormal metabolic signals in type 2 diabetes. The approach is experimental, but it points to a future where managing diabetes does not always mean another prescription.
Food as Medicine: The Mixed Results
One of the most talked-about ideas in U.S. diabetes care is "food is medicine," and the trial data is genuinely split. A large practical trial run by Kaiser Permanente Northern California gave low-income patients with high-risk type 2 diabetes a monthly stipend for healthy groceries through an online delivery service. After six months, blood sugar barely budged. The researchers concluded that making healthy food affordable alone is not enough, that people likely need nutrition education, cooking guidance, or more intensive behavioral support alongside the groceries.
The contrast came from a University of North Carolina trial that compared medically tailored meals to a simple grocery subsidy. Participants who received weekly deliveries of dietitian-designed meals, combined with phone-based lifestyle coaching, saw their HbA1c drop roughly 0.4% more than those who just got money for groceries. They also had meaningfully lower systolic blood pressure. In other words, the form of support matters as much as the food itself.
This is a useful reminder if you are managing diabetes on a budget. Free delivery does not fix everything, and neither does handing someone cash for vegetables. What seems to work is a package that combines the right food with coaching and consistency.
What the Latest Drug Trials Actually Show
The medication pipeline is moving fast, and the numbers coming out of phase 2 and phase 3 trials are striking. One new single-molecule drug that targets both GLP-1 and amylin receptors lowered HbA1c significantly more than placebo across most doses in a 36-week trial, with 76% of people in the top dose group reaching an HbA1c of 6.5% or below. Weight loss followed a similar pattern, with the highest dose producing substantially greater reductions than placebo.
Another approach, a triple-hormone therapy that combines three different receptor targets, delivered some of the largest weight-loss results ever seen in a type 2 diabetes drug program. In the phase 3 data, roughly two-thirds of people in the highest dose group achieved both good glucose control and a weight loss of at least 10%. The drug also showed benefits for obstructive sleep apnea and knee osteoarthritis, which many people with diabetes also struggle with.
Fixed-dose combinations are another trend. The combination of semaglutide with a new amylin analog showed meaningful HbA1c reductions and weight loss across three different type 2 diabetes populations in the REIMAGINE studies. Side effects were mostly mild to moderate gastrointestinal issues, which is typical for this class of medications. These results were published in the Lancet family of journals, giving them solid scientific backing.
| Category | Example Solution | Dosing | Best For | Strengths | Watch Out For |
|---|
| Oral GLP-1 | Orforglipron | Daily pill | People who prefer pills over injections | No injection, proven phase 3 results | GI side effects, still being studied long-term |
| Injectable GLP-1/amylin | Zenagamtide | Weekly or daily | People seeking strong glucose and weight control | Large HbA1c and weight reductions | Nausea during dose escalation |
| Triple-hormone therapy | Retatrutide | Weekly injection | People with obesity plus type 2 diabetes | Largest weight-loss data in T2D trials | Low blood pressure risk with BP meds |
| Fixed-dose combo | CagriSema | Weekly injection | People needing help with both glucose and weight | Two-in-one effect in one shot | GI side effects typical of GLP-1s |
| CGM devices | Various models | Wear continuous | People on insulin or with unpredictable lows | Real-time data, fewer hypoglycemia events | Cost and insurance coverage vary |
| Food as medicine | Medically tailored meals | Weekly delivery | People facing food insecurity | Measurable HbA1c and BP improvements | Needs coaching to work best |
How to Find and Join a Diabetes Trial Near You
If you are thinking about joining a trial, start with your own care team. Endocrinologists and diabetes educators often hear about studies before the general public does, and they can tell you whether a trial fits your health profile. Academic medical centers across the country, places like UNC Health, Duke, and Kaiser Permanente systems, regularly run diabetes research, and many post open studies on their websites.
ClinicalTrials.gov remains the most reliable directory. You can filter by condition, state, and whether the trial is actively recruiting. Many listings include eligibility criteria, so you can check your age, diabetes type, current medications, and HbA1c range before contacting anyone. It saves a lot of time.
A few practical things to keep in mind. First, most trials cover the cost of the investigational treatment and the study-related visits, which can reduce out-of-pocket expenses compared to standard care. Ask the coordinator exactly what is covered, because coverage of travel and time is not guaranteed. Second, you can leave a trial at any time, and your regular diabetes care should continue as usual either way. Third, understand that an investigational drug has known and unknown risks, and you will be told about the known ones in detail before you sign.
Reach out to a couple of centers rather than just one. Trials have specific enrollment windows, and a study that is full at one site might be starting at another. Local chapters of the American Diabetes Association and JDRF for type 1 diabetes also maintain lists of research opportunities, and they can connect you with community-based studies that may feel more accessible.
Moving Forward With Better Options
The diabetes landscape in America looks nothing like it did a few years ago. Oral pills that rival injectable effectiveness, single injections that tackle blood sugar and weight together, and even endoscopic procedures are all in active testing. What works for one person will not work for another, which is exactly why trials matter. They let researchers figure out who benefits most and under what conditions.
If your current routine is working, there is no reason to change it. But if you have hit a plateau, struggle with side effects, or find the cost of newer options hard to manage, a clinical trial could be a practical path forward. Talk to your doctor about what you are hoping to improve, whether that is your HbA1c, your weight, or your energy level, and ask whether any local studies match those goals. The research is happening now, in your state, at centers you may already drive past. The next breakthrough might be a pill you take in the morning, a sensor you wear on your arm, or a meal delivered to your door. It starts with a conversation and a willingness to ask what is available near you.
研究の知恵